APLM PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

APLM ▲ +6.82% at T+20d

LONG call ✓ call won +6.82% · α vs SPY +1.86% · entry $13.19 → $14.09

Next anchor: T+60d in 5w

Last close $14.31 (close Jun 12) · +8.45% from $13.19 entry

Entry anchored
Apr 24, 11:34 AM ET
via Databento tick

T+1d

-2.58%

call -2.58% · α -2.09%

$12.85

settled 7w ago

T+5d

+24.84%

call +24.84% · α +24.44%

$16.47

settled 6w ago

T+20d

+6.82%

call +6.82% · α +1.86%

$14.09

settled 20d ago

T+60d

—

call — · α —

—

in 5w

Price Chart

Loading chart...

Executive Summary

Apollomics reported its 2025 full-year financial results, posting $8.5M in revenue from a licensing deal with LaunXP, a significant improvement from $0 in 2024. The company reduced operating expenses by 64% year-over-year and ended 2025 with $3.3M in cash, though net loss narrowed to $(10.9M) from $(53.9M) in 2024. Pipeline progress includes advancing vebreltinib in global Phase 2 trials and planning a U.S. IND submission by 2027.

Actionable Insight

The sharp reduction in losses and return to revenue via a licensing deal signal operational stabilization after a turnaround. Monitor upcoming clinical data readouts and IND submission timing for vebreltinib, which could catalyze further upside despite limited cash reserves.

Key Facts

Revenue for 2025 was $8.5 million (vs. $0 in 2024), driven by upfront payment from LaunXP licensing agreement.
Operating expenses dropped 64% YoY to $19.8M from $55.7M in 2024, due to cost reduction initiatives.
Net loss narrowed significantly to $(10.9M) in 2025 from $(53.9M) in 2024.
Cash balance was $3.3M as of December 31, 2025, down from $9.8M at end of 2024.
Vebreltinib (APL-101) is in ongoing global Phase 2 SPARTA trial with over 282 patients enrolled; U.S. IND submission planned for first half of 2027.

Financial Impact

$8.5M in new licensing revenue, operating expenses cut by $35.9M YoY

revenueoperating expensesnet losscash

Risk Factors

Cash balance of $3.3M may not be sufficient to fund ongoing global trials without dilutive financing.
Revenue was non-recurring (upfront licensing payment), so future top-line growth depends on new deals or approvals.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

86% bullish (7 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3281561

US Market Status

Market Closed — Opens in 3h 59m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access